Menu
The drug is typically used for individuals with type 2 diabetes to improve blood sugar levels in adults. It is also indicated for patients with chronic weight management issues in adults or children 12 or over with obesity, some adults with excess weight, or patients who have other weight-related medical conditions who need to lose weight and keep it off.
Adults would typically have an initial body mass index (BMI) of ≥30 kg/m2 (obesity) or ≥27 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia)
Pediatric patients aged 12 years and older would typically have an initial BMI at the 95th percentile or greater standardized for age and sex (obesity)
Discover the transformative power of NanoDropsRX’s AQASome NPc Semaglutide, an innovative solution for managing weight and enhancing overall health through a convenient oral delivery system. Leveraging advanced nanotechnology, our AQASome NPc formulation replaces traditional injections with easy-to-use oral drops, simplifying your journey to better health
Not all medicines are a one-size fit all. People don’t like injections, they can’t take pills or maybe they are suffering from poor absorption. Standard dosing comes with negative side effects and traditional medicines are difficult to dial in dosing. NDRx and the proprietary AQASOME NPC (nano particle carrier) compounding technology is a major advance to allow for significant patient benefits.
AQA Oral Semaglutide is designed to maintain a roughly 1:1 dosing ratio with injectable Semaglutide, allowing for similar therapeutic effects through oral administration.
The oral solution form allows for titratable dosing, making it adaptable to individual patient needs, including pediatric dosing and adjustments based on patient weight and tolerance.
AQA Oral Semaglutide is compounded with soluble fibers that protect the active ingredient from degradation in the gastrointestinal tract, ensuring consistent absorption through the intestinal lymphatic system.
Unlike injectable Semaglutide, AQA SG can be administered easily as an oral solution, which is less invasive and potentially more acceptable for patients who are averse to injections.
Patients typically experience a reduction in appetite, quicker satiation with smaller meals, and prolonged fullness, which aids in weight management.
Starting at lower doses and gradually increasing can help minimize common side effects such as nausea and vomiting, allowing patients to find an optimal dose with fewer adverse reactions.
